Orbimed Advisors LLC C4 Therapeutics, Inc. Transaction History
Orbimed Advisors LLC
- $2.93 Billion
- Q3 2025
A detailed history of Orbimed Advisors LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 5,235,146 shares of CCCC stock, worth $12.9 Million. This represents 0.4% of its overall portfolio holdings.
Number of Shares
5,235,146
Previous 6,830,300
23.35%
Holding current value
$12.9 Million
Previous $9.77 Million
18.99%
% of portfolio
0.4%
Previous 0.35%
Shares
4 transactions
Others Institutions Holding CCCC
# of Institutions
108Shares Held
55.4MCall Options Held
329KPut Options Held
186K-
Lynx1 Capital Management LP San Juan, PR7.1MShares$17.5 Million3.06% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.05MShares$17.4 Million0.95% of portfolio
-
Morgan Stanley New York, NY4.97MShares$12.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$12 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$11.2 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $121M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...